(Q37949638)

25 August 2017

title

Drug combinations for HIV: what's new? (English)

1 reference

25 August 2017

Andrew Scourfield

1

1 reference

25 August 2017

Laura Waters

series ordinal

2

1 reference

25 August 2017

Mark Nelson

series ordinal

3

1 reference

25 August 2017

publication date

1 November 2011

1 reference

Expert Review of Anti-infective Therapy

25 August 2017

published in

1 reference

25 August 2017

volume

9

1 reference

25 August 2017

issue

11

1 reference

25 August 2017

page(s)

1001-1011

1 reference

Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy.

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

Noncirrhotic portal hypertension in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

Interactions between protease inhibitors and acid-reducing agents: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

Age-disparate and intergenerational sex in southern Africa: the dynamics of hypervulnerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

A randomized crossover study to compare efavirenz and etravirine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE st

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

Class-sparing regimens for initial treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

Interleukin-2 therapy in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

Antivirals and antiviral strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.125

21 January 2018

Identifiers

DOI

10.1586/ERI.11.125

1 reference

25 August 2017

1 reference